• category:Pipeline
Positive topline data reported in EyePoint's phase 2 wet AMD trial
Pipeline

Positive topline data reported in EyePoint's phase 2 wet AMD trial

EYP-1910 demonstrates a favorable safety profile in DAVIO 2 study, meeting all endpoints.
Aldeyra's NDA for reproxalap requires more studies, FDA says
Pipeline

Aldeyra's NDA for reproxalap requires more studies, FDA says

Company response letter follows the submission of a special protocol assessment for a crossover trial.
Kodiak is restarting its tarcocimab clinical program for three retinal disease indications
Pipeline

Kodiak is restarting its tarcocimab clinical program for three retinal disease indications

FDA approves initiation of first inflammasome inhibitor trial for GA
Pipeline

FDA approves initiation of first inflammasome inhibitor trial for GA

Use of Kamuvudines via a sustained release delivery system could prevent the process that causes GA.
Pixium Vision releases 48-month study data for severe atrophic AMD
Pipeline

Pixium Vision releases 48-month study data for severe atrophic AMD

Trial results on the PRIMA Bionic Vision System indicate promising safety and efficacy.
EyesBio expands financing for advanced development of Restoret
Pipeline

EyesBio expands financing for advanced development of Restoret

Funding now totals $130 million, supporting the ongoing phase 1b/2a AMARONE trial.
FDA grants RMAT designation for Atsena's LAC1 gene therapy
Pipeline

FDA grants RMAT designation for Atsena's LAC1 gene therapy

Positive 6-month data on ATSN-101 supports designation; 12-month results expected by end of 2023.
Focusing in: Surgical innovation highlights at AAO
Pipeline

Focusing in: Surgical innovation highlights at AAO

Eric Donnenfeld, MD, FAAO, FACS, shares clinical updates on two innovative technologies and his pick for a must-attend session.
Positive 1-year data reported in ALTITUDE gene therapy trial
Pipeline

Positive 1-year data reported in ALTITUDE gene therapy trial

Ongoing phase 2 trial reports potential for one-time injection in managing DR.
OnPoint Vision's IDE app for IOPCL Magnifier earns FDA approval
Pipeline

OnPoint Vision's IDE app for IOPCL Magnifier earns FDA approval

Paves the way for a phase 1 pivotal trial on AccuraSee, designed to securely pair with any pre-existing IOL located within the capsular bag.
Aldeyra and AbbVie agree to exclusive licensing option for reproxalap
Pipeline

Aldeyra and AbbVie agree to exclusive licensing option for reproxalap

Agreement follows FDA concerns regarding the DED investigational compound’s clinical data.
Enrollment concludes for ViaLase's pivotal  POAG laser trial
Pipeline

Enrollment concludes for ViaLase's pivotal POAG laser trial

First femtosecond laser image-guided high-precision trabeculectomy (FLigHT) offers the potential as a non-invasive treatment.
Ocular Therapeutix initiates first pivotal trial of implant for wet AMD
Pipeline

Ocular Therapeutix initiates first pivotal trial of implant for wet AMD

OTX-TKI offers the potential for long-term durability with fewer injections.
FDA clears Endogena's IND for GA investigational compound
Pipeline

FDA clears Endogena's IND for GA investigational compound

A first-in-human study for EA-2351 is set to kick off in 2024.
Glaukos acquires global rights to Stuart Therapeutics' neuroprotection glaucoma asset
Pipeline

Glaukos acquires global rights to Stuart Therapeutics' neuroprotection glaucoma asset

Proprietary therapeutic has been shown to function independently of IOP control.
Positive data released for Aviceda's phase 2/3 GA trial
Pipeline

Positive data released for Aviceda's phase 2/3 GA trial

Findings report on first three months of part 1 evaluating AVD-104 in the SIGLEC trial.
Aldeyra's reproxalap faces FDA concerns
Pipeline

Aldeyra's reproxalap faces FDA concerns

Agency identifies substantive review issues with the dry eye disease candidate
New 6-month data evaluates AZR-MD-001 for MGD
Pipeline

New 6-month data evaluates AZR-MD-001 for MGD

Presented at AAOPT, latest findings follow previous 3-month data evaluating the efficacy of two dosages.
Positive 4-year data reported from phase 3 CHAMP study for pediatric myopia
Pipeline

Positive 4-year data reported from phase 3 CHAMP study for pediatric myopia

Latest data on NVK002 builds on previous 3-year results released in May 2023.
OKYO Pharma submits NDA for neuropathic corneal pain treatment
Pipeline

OKYO Pharma submits NDA for neuropathic corneal pain treatment

Pending FDA acceptance, phase 2 clinical trial is planned to commence in Q1 2024.